Abstract:
The triple negative breast cancer (TNBC) subtype is known to have a more
aggressive clinical course compared to other breast cancer subtypes. Targeted
therapy for this type of breast cancer is limited, and patients are primarily
treated with conventional chemotherapy and radiotherapies, which are not
specific and do not target resistant cells. Thus, one of the major clinical
challenges is to find compounds that target drug-resistant cell populations
responsible for the transformation of secondary tumors. Molecular profiling of
different TNBC subtypes offers hope for better identifying these tumor-specific
resistant cells. To this end, a better understanding of TNBC heterogeneity and
cancer stemness is required . and extensive genomic analysis can help
understand the complexity of the disease and highlight new molecular drivers
that can be targeted in the clinic. The use of therapies targeting persistent
cancer cells in combination with other treatments may provide major advances
in improving survival for patients with TNBC.
